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of mutations at cDNA level thus enables the detection of a broader spec-
trum of mutations, and provides a greater understanding of their molec-
ular pathogenesis (Messiaen et al., 2000; Pros et al., 2008; Valero et al.,
2011). The mutation collection provided by Evans and colleagues is
therefore very useful for molecular diagnosis, in particular because the
functional effects of variation were assessed at mRNA level.NF1
SPRED1
RNANeuroﬁbromatosis type 1 (NF1) is one of the most common autoso-
mal dominant disorders and is caused by mutations in the NF1
(Neuroﬁbromin 1) gene. More than half of all NF1 cases are caused by
de novo sporadic mutations. Mutation detection is challenging owing
to the large size of the NF1 gene, the presence of numerous
pseudogenes, and the great variety of possible alterations. Recurrent
NF1 locus large deletions (found in 5 to 10% of NF1 patients) have
been associated with more severe and atypical manifestations
(Pasmant et al., 2010).
In this issue of EBioMedicine, Evans and colleagues report their expe-
rience with a RNA-based NF1 genemutation analysis in the English NF1
reference laboratory between 2009 and 2015 (Evans et al., 2016). A
comprehensive cDNA analysis coupled with multiplex ligation-depen-
dent probe ampliﬁcation (MLPA) at DNA level (for large deletions de-
tection) was performed in a cohort of 361 English NF1 patients.
The aim of the study was to present a molecular strategy for NF1 al-
teration detection focused on a cDNA-targeted approach by Sanger se-
quencing. This cDNA-based approach was previously modelled
(Messiaen et al., 2000; Pros et al., 2008; Valero et al., 2011; Sabbagh et
al., 2013). However, this study by Evans and colleagues provides impor-
tant information on the effectiveness of screening a large cohort of NF1
patients. Moreover, they provide a comprehensive list of annotated mu-
tations. Interpretation of NF1 variants is challenging (in particular for
missense and in frame variations): a huge number of different pathogen-
ic mutations have been reported in the tumour suppressor gene NF1. It
appears that a signiﬁcant proportion of NF1 missense mutations isom.2016.04.005.
Genetics and Biology, Cochin
mant).
. This is an open access article underdeleterious by affecting normal pre-mRNA splicing. The characterization
Evans and colleagues also underlined that sequencing at the cDNA
level can increase mutation detection sensitivity due to the presence
of deep intronic mutations, or exons deletions (Imbard et al., 2015).
Their screen for NF1 gene lesions identiﬁed ~96% of pathological muta-
tions in patients presentingwith typical NF1, using a two-step approach
including a cDNA Sanger sequencing and copy number variations (CNV)
study. This high mutation detection sensitivity can be achieved in well
phenotypedNF1 patients. It is comparable to the one obtainedwith pre-
vious screening methodologies, conﬁrming the interest of this mRNA-
based approach (Messiaen et al., 2000; Pros et al., 2008; Valero et al.,
2011; Sabbagh et al., 2013; Pasmant et al., 2015). In the study by
Evans and colleagues, RNA was isolated from short-term phytohemag-
glutinin (PHA) cultures pre-treated before RNA extraction with Puro-
mycin to inhibit nonsense mediated decay. Short term PHA culture
allows better control of the cell culture conditions and avoidance of spu-
rious alternative splicing andmRNA decay. However, in our experience,
an approach using PAXgene™ Blood RNASystem (Qiagen)may simplify
and shorten the process, allowing stabilization of RNA at the time of
sample collection, and avoiding artefacts introduced during sample
handling (Sabbagh et al., 2013).
A correct NF1 diagnosis has important implications for prognosis,
counseling, and prenatal diagnosis.Molecular diagnosis inNF1 is helpful
to conﬁrm the clinical diagnosis, notably in patients with
paucisymptomatic, pediatric, or segmental presentations. In young chil-
dren, café-au-lait macules are often the only clinical ﬁndings. In these
cases, mutation analysis of the NF1 gene may clarify the diagnosis if de
novo. Clinical applications of mutational analysis have increased in rele-
vance since some clear genotype-phenotype correlations have been
identiﬁed (in patients with large NF1 locus deletions, missense muta-
tions affecting codon p.Arg1809, or inframe deletions of codon
p.Met992) and because of clinical overlap with the Legius syndrome
(Pasmant et al., 2012). Limited genetic heterogeneity has been found
in NF1 by identiﬁcation of the Legius syndrome, caused by mutations
in the SPRED1 gene encoding a negative regulator of the RAS-MAPK
pathway (Brems et al., 2012). SPRED1mutations are rare compared to
NF1mutations. Patients with Legius syndrome have multiple café-au-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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associated tumours. Because of the important clinical overlap with
NF1, it is impossible to diagnose the syndrome exclusively based on
clinical feature alone. In patients presenting solely with café-au-lait
spots and/or frecklings, a molecular conﬁrmation has to be performed.
Molecular diagnosis is essential because distinguishing between
NF1 and Legius syndrome is important for prognosis and clinical
management.
Evans and colleagues also report six variants in an evolutionary con-
served region of the NF1 5′ untranslated region (UTR), with bi-allelic
NF1 expression and a de novo occurrence in one case. This interesting
ﬁnding suggests a previously unreported mechanism of NF1 loss-of-
function that needs further experimentation. Finally, for the remaining
~4% of NF1 patients with no molecular conﬁrmation after NF1 and
SPRED1 screening, a whole exome sequencing approach could be used
to search for additional NF1 phenotype disease loci.
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